The anthracycline drugs -- long a mainstay of breast cancer chemotherapy -- only benefit a minority of women and should be mostly scrapped, a researcher said here.Read the full article here:
The continued use of the drugs "on a one-size-fits-all approach is just crazy and it's medically dangerous," said Dennis Slamon, M.D., Ph.D., of the University of California at Los Angeles.
Friday, December 14, 2007
A New Warning for Women with Breast Cancer
Yes, one size does not fit all and it is about time MSM woke up to tell you...